Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 in Bronchiectasis
NCT06987214Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- May 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bronchial basal cells in bronchiectasis, sponsored by Ruijin Hospital. Primary endpoint: Diffusing capacity of the lungs for carbon monoxide at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
autologous bronchial basal cells
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06987214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987214.